HSP Co-modulator Program
Alzheimer's Disease
About LipidArt
LipidArt is a private, preclinical-stage biotech leveraging a proprietary platform to develop heat shock protein (Hsp) co-modulators for neurodegenerative disorders and oncology. Its lead candidates have shown promising efficacy in animal models of Alzheimer's disease and in various tumor models. The company's approach aims to selectively target cells under pathological stress, potentially offering a novel therapeutic strategy with a high safety profile. It is guided by a strong scientific advisory board with expertise in chaperone biology and related disease mechanisms.
View full company profileAbout LipidArt
LipidArt is a private, preclinical-stage biotech leveraging a proprietary platform to develop heat shock protein (Hsp) co-modulators for neurodegenerative disorders and oncology. Its lead candidates have shown promising efficacy in animal models of Alzheimer's disease and in various tumor models. The company's approach aims to selectively target cells under pathological stress, potentially offering a novel therapeutic strategy with a high safety profile. It is guided by a strong scientific advisory board with expertise in chaperone biology and related disease mechanisms.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |